Therapeutic Areas

Oncology & Hematology Expertise

Cancer Clinical Development is Complex, Our Experts Can Help

When the complexities of designing and executing cancer trials in a highly competitive market can mean delays in delivering urgently needed treatments to patients, it pays to have a trusted partner by your side. In the past five years, our experienced teams have helped clients with more than 300 oncology studies and have worked on more than 30 US and European regulatory marketing applications for cancer treatments, including many rare cancers.

Our extensive expertise includes traditional cancer treatments, devices/diagnostics as well as specialized therapies including vaccines, gene therapies, cell therapies, and immunotherapies.

Specialized Oncology CRO from Consultation to Beyond Submission

Our solutions span the entire clinical development life-cycle - and are offered as a comprehensive, all-inclusive solution or as functional support. We provide strategic guidance for informed decision-making, operational support to mitigate trial risks, the statistical knowledge to prove safety and efficacy, the medical oversight to ensure patient safety, and the regulatory expertise to achieve approval success.

Solid Tumors Including:
Brain	Head and Neck
Breast	Liver
Gastrointestinal	Lung
Genitourinary including prostate, renal and bladder cancers	Skin including melanoma
Gynecologic

Rare Cancers Including:
Acute Myeloid Leukemia	Multiple Myeloma
Chronic Lymphocytic Leukemia	Myelodysplastic Syndrome
Glioblastoma	Ovarian
Hodgkin's Lymphoma	Pancreatic

US & EU approval for an ultra-rare hematologic malignancy

Regulatory Submission Strategy and Novel Efficacy Endpoint for Treatment of an Ultra-Rare and Aggressive Hematologic Malignancy lead to approval from the FDA and EMA

Focus on Hematology

Veristat has guided clients through the successful conduct of more than 275 hematology projects and has prepared more than 35 marketing applications for blood diseases. Our experience spans clinical development consulting, full clinical trial oversight, and regulatory submission preparation for a broad range non-malignant and malignant hematologic conditions including Leukemias, Lymphomas, and Myelomas.

Some of the rarest hematology indications include complex cell and gene therapeis for diseases such as Beta-Thalasemia, Sickle Cell Disease, Hemophilia and Wiskott-Adrich Syndrome (WAS).